References
- Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2004; 18: 13–26
- Veraldi S, Menter A., Innocenti M. Treatment of mild to moderate seborrheic dermatitis with MAS064D (Sebclair), a novel topical medical device: Results of a pilot, randomized, double-blind, controlled trial. J Eur Acad Dermatol Venereol. 2008; 22: 290–6
- Sugita T, Tajima M, Tsubuku H, Tsuboi R, Nishikawa A. A new calcineurin inhibitor, pimecrolimus, inhibits the growth of Malassezia spp. Antimicrob Agents Chemother. 2006; 50: 2897–8
- Rigopoulos D, Ionnides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1% vs betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis: A randomized open-label clinical trial. Br J Dermatol. 2004; 151: 1071–5
- Rallis E, Nasiopoulou A, Kouskoukis C, Koumantaki E. Pimecrolimus cream 1% can be an effective treatment of seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res. 2004; 30: 191–5
- High WA, Pandya AG. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J Am Acad Dermatol. 2006; 54: 1083–8
- Firooz A, Solhpour AM, Gorouhi F, Daneshpazhooh M, Balighi K, Farsinejad K, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: A randomized, investigator-blind, clinical trial. Arch Dermatol. 2006; 142: 1066–7
- Warshaw EM, Wohlhuter RJ, Liu A, Zeller SA, Wenner RA, Bowers S, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 2007; 57: 257–64
- De Moraes AP, de Arruda EA, Vitoriano MAV, de Moraes Filho MO, Bezerra FA, de Magalhaes Holanda E, et al. An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrheic dermatitis infected with HIV. J Eur Acad Dermatol Venereol. 2007; 21: 596–601
- Kim BS, Kim SH, Kim MB, Oh CK, Jang HS, Kwon KS. Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: An open-label clinical study in Korean patients. J Korean Med Sci. 2007; 22: 868–72
- Koc E, Arca E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat. 2008; 1: 1–5